{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T10:58:54Z","timestamp":1787828334084,"version":"build-2784847793"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,1,22]],"date-time":"2019-01-22T00:00:00Z","timestamp":1548115200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2019.00006","type":"journal-article","created":{"date-parts":[[2019,1,22]],"date-time":"2019-01-22T09:58:44Z","timestamp":1548151124000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["A Multicenter Phase II Trial of Docetaxel, Cisplatin, and Cetuximab (TPEx) Followed by Cetuximab and Concurrent Radiotherapy for Patients With Local Advanced Squamous Cell Carcinoma of the Head and Neck (CSPOR HN01: ECRIPS Study)"],"prefix":"10.3389","volume":"9","author":[{"given":"Sadamoto","family":"Zenda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Ota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi","family":"Kiyota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susumu","family":"Okano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morimasa","family":"Kitamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunji","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsutomu","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuya","family":"Monden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeharu","family":"Yamanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Tahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,1,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1054\/bjoc.2000.1512","article-title":"Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma. French Groupe d'Etude des Tumeurs de la Tete et du Cou (GETTEC)","volume":"83","author":"Domenge","year":"2000","journal-title":"Br J Cancer"},{"key":"B2","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1093\/jnci\/86.4.265","article-title":"Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: a study by the Gruppo di Studio sui Tumori della Testa e del Collo","volume":"86","author":"Paccagnella","year":"1994","journal-title":"J Natl Cancer Inst"},{"key":"B3","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1093\/jnci\/djp007","article-title":"Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation","volume":"101","author":"Pointreau","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1056\/NEJMoa071028","article-title":"Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer","volume":"357","author":"Vermorken","year":"2007","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1056\/NEJMoa070956","article-title":"Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer","volume":"357","author":"Posner","year":"2007","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.radonc.2009.04.014","article-title":"Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients","volume":"92","author":"Pignon","year":"2009","journal-title":"Radiother Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1093\/annonc\/mdv268","article-title":"Cetuximab, docetaxel, and cisplatin as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma: a multicenter, phase II GORTEC study","volume":"26","author":"Guigay","year":"2015","journal-title":"Ann Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.1200\/JCO.2015.62.3488","article-title":"Recommendations for the use of wbc growth factors: american society of clinical oncology clinical practice guideline update","volume":"33","author":"Smith","year":"2015","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1056\/NEJMoa053422","article-title":"Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck","volume":"354","author":"Bonner","year":"2006","journal-title":"New Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"907","DOI":"10.4143\/crt.2015.359","article-title":"The effect of induction chemotherapy using docetaxel, cisplatin, and fluorouracil on survival in locally advanced head and neck squamous cell carcinoma: a meta-analysis","volume":"48","author":"Kim","year":"2016","journal-title":"Cancer Res Treat"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.1200\/JCO.2013.54.6309","article-title":"Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer","volume":"32","author":"Cohen","year":"2014","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/S1470-2045(13)70011-1","article-title":"Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial","volume":"14","author":"Haddad","year":"2013","journal-title":"Lancet Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1093\/annonc\/mdt461","article-title":"A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer","volume":"25","author":"Hitt","year":"2014","journal-title":"Ann Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1093\/annonc\/mdp573","article-title":"Concomitant chemoradiotherapy versus induction docetaxel, cisplatin and 5 fluorouracil (TPF) followed by concomitant chemoradiotherapy in locally advanced head and neck cancer: a phase II randomized study","volume":"21","author":"Paccagnella","year":"2010","journal-title":"Ann Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1093\/annonc\/mdx300","article-title":"TPF plus cetuximab induction chemotherapy followed by biochemoradiation with weekly cetuximab plus weekly cisplatin or carboplatin: a randomized phase II EORTC trial","volume":"28","author":"Specenier","year":"2017","journal-title":"Ann Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.radonc.2011.09.016","article-title":"Multicenter phase II study of an opioid-based pain control program for head and neck cancer patients receiving chemoradiotherapy","volume":"101","author":"Zenda","year":"2011","journal-title":"Radiother Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"3029","DOI":"10.1007\/s00520-016-3122-5","article-title":"Multicenter phase II study of an oral care program for patients with head and neck cancer receiving chemoradiotherapy","volume":"24","author":"Yokota","year":"2016","journal-title":"Supportive Care Cancer"},{"key":"B18","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1093\/jjco\/hyv010","article-title":"DeCoP, a Dermatitis Control Program using a moderately absorbent surgical pad for head and neck cancer patients receiving radiotherapy: a retrospective analysis","volume":"45","author":"Zenda","year":"2015","journal-title":"J Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1007\/s10147-012-0385-9","article-title":"A Dermatitis Control Program (DeCoP) for head and neck cancer patients receiving radiotherapy: a prospective phase II study","volume":"18","author":"Zenda","year":"2013","journal-title":"Int J Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s12885-016-2073-z","article-title":"Asian expert recommendation on management of skin and mucosal effects of radiation, with or without the addition of cetuximab or chemotherapy, in treatment of head and neck squamous cell carcinoma","volume":"16","author":"Zhu","year":"2016","journal-title":"BMC Cancer"},{"key":"B21","doi-asserted-by":"publisher","first-page":"5294","DOI":"10.1200\/JCO.2010.30.6423","article-title":"Induction docetaxel, cisplatin, and cetuximab followed by concurrent radiotherapy, cisplatin, and cetuximab and maintenance cetuximab in patients with locally advanced head and neck cancer","volume":"28","author":"Argiris","year":"2010","journal-title":"J Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1002\/hed.21081","article-title":"Larynx preservation clinical trial design: key issues and recommendations\u2013a consensus panel summary","volume":"31","author":"Lefebvre","year":"2009","journal-title":"Head Neck"},{"key":"B23","doi-asserted-by":"publisher","first-page":"6625","DOI":"10.21873\/anticanres.11269","article-title":"Laryngo-esophageal dysfunction-free survival in a preservation protocol for T3 laryngeal squamous-cell carcinoma","volume":"36","author":"Gorphe","year":"2016","journal-title":"Anticancer Res"},{"key":"B24","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1177\/0003489415588130","article-title":"Treatment selection for T3\/T4a laryngeal cancer: chemoradiation versus primary surgery","volume":"124","author":"Timme","year":"2015","journal-title":"Ann Otol Rhinol Laryngol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S0140-6736(18)32752-1","article-title":"Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial","volume":"393","author":"Mehanna","year":"2019","journal-title":"Lancet"},{"key":"B26","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S0140-6736(18)32779-X","article-title":"Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial","volume":"393","author":"Gillison","year":"2019","journal-title":"Lancet"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2019.00006\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,22]],"date-time":"2019-01-22T09:58:45Z","timestamp":1548151125000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2019.00006\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,22]]},"references-count":26,"alternative-id":["10.3389\/fonc.2019.00006"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2019.00006","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,22]]},"article-number":"6"}}